Showing 7021-7030 of 8815 results for "".
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Ted Danson Partners with Bristol Myers Squibb for Plaque Psoriasis Campaignhttps://practicaldermatology.com/news/ted-danson-partners-with-bristol-myers-squibb-for-plaque-psoriasis-campaign/2462442/Bristol Myers Squibb has partnered with award-winning actor Ted Danson, who lives with plaque psoriasis, for a new campaign called “
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t
- Povorcitinib Shows Efficacy and Safety in Patients with Prurigo Nodularishttps://practicaldermatology.com/news/study-povorcitinib-safe-and-effective-for-prurigo-nodularis/2462426/The oral JAK1 inhibitor povorcitinib was shown to improve itch in prurigo nodularis, and also met its primary endpoints, according to new phase 2 data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the study enrolled 146 participants and
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in
- Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasishttps://practicaldermatology.com/news/thermo-fisher-scientific-launches-corevitas-clinical-registry-in-generalized-pustular-psoriasis/2462265/Thermo Fisher Scientific announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RW